{
  "meta": {
    "title": "Bleeding_And_Clotting_Disorders_Mini_Test_-_Tmt",
    "url": "https://brainandscalpel.vercel.app/bleeding-and-clotting-disorders-mini-test-tmt-e6eb3980.html",
    "scrapedAt": "2025-11-30T12:46:48.402Z"
  },
  "questions": [
    {
      "text": "A boy presented with a painful right knee swelling as seen in the image. He has a history of easy bruising and hematoma formation at injection sites. His lab investigation report is given below. Which of the following is the preferred treatment option for this condition?<div class='question-desc-html'><ul>\n<li>Platelet count - 4,00,000 /μL</li>\n<li>Bleeding time - Normal</li>\n<li>PT - Normal</li>\n<li>aPTT - Prolonged</li>\n</ul></div>",
      "choices": [
        {
          "id": 1,
          "text": "Factor VIII concentrate"
        },
        {
          "id": 2,
          "text": "Cryoprecipitate"
        },
        {
          "id": 3,
          "text": "Fresh frozen plasma"
        },
        {
          "id": 4,
          "text": "Whole blood transfusion"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The image showing knee joint swelling in a patient with bleeding tendency and prolonged aPTT indicates bleeding into the joint space, i.e. <strong>hemarthrosis</strong> due to <strong>hemophilia</strong>. The preferred treatment option among the ones given here is the administration of<strong> factor VIII concentrate.</strong></p>\n<p><strong>Hemophilia</strong> is a coagulation disorder occurring due to a deficiency of <strong>clotting factor VIII</strong>, leading to <strong>hemophilia A,</strong> or <strong>clotting factor IX</strong>, leading to<strong> hemophilia B</strong>. Hemophilia<strong> </strong>A and B are <strong>clinically indistinguishable </strong>and can be differentiated based on<strong> clotting factor assay.</strong> The disorder is X-linked recessive, meaning males are affected, and females are asymptomatic carriers.</p>\n<p>Patients present with bleeding tendencies such as ecchymoses, epistaxis, haematuria, menorrhagia, hemarthrosis, prolonged bleeding after dental or minor surgical procedures, etc. <strong>Repeated hemarthrosis</strong> causes chronic <strong>synovitis</strong> and articular <strong>cartilage erosion</strong>, leading to <strong>hemophilic arthritis.</strong></p>\n<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Laboratory findings</strong> in hemophilia:</p>\n<ul>\n<li><strong>Activated partial thromboplastin time</strong> (aPTT) -<strong> prolonged</strong></li>\n<li>Platelet count- normal</li>\n<li>Bleeding time- normal</li>\n<li>Prothrombin time- normal</li>\n<li>The mixing of normal plasma with patient plasma results in the correction of the aPTT value.</li>\n</ul>\n<p>Based on the percent activity of specific clotting factors, hemophilia is classified into:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Severity</strong></td>\n<td><strong>The activity of a specific clotting factor</strong></td>\n</tr>\n<tr>\n<td>Severe</td>\n<td>&lt;1%</td>\n</tr>\n<tr>\n<td>Moderate</td>\n<td>1-5%</td>\n</tr>\n<tr>\n<td>Mild</td>\n<td>&gt;5%</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong><br />Mild</strong> cases of hemophilia are <strong>treated</strong> by administration of <strong>desmopressin acetate. Moderate</strong> to <strong>severe</strong> cases need the <strong>replacement</strong> of deficient <strong>clotting factors. </strong>The monoclonal antibody <strong>emicizumab</strong> can bridge activated factor IX and factor X, thus restoring functional activated factor VIII activity in patients with hemophilia.</p>\n<p>Please note that this patient could have either hemophilia A or B. The preferred treatment options for hemophilia are the administration of factor VIII and factor IX for hemophilia A and B, respectively. As factor IX is not given in the options, factor VIII is the best possible answer.</p>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Blood components</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Volume     (1 unit)</strong></td>\n<td><strong>Content</strong></td>\n<td><strong>Clinical response, increase in </strong></td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>Shelf-life</strong></td>\n</tr>\n<tr>\n<td>Whole blood</td>\n<td>450 ml</td>\n<td>RBCs, platelets, plasma</td>\n<td>Hb and plasma volume</td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>Packed red blood cells (PRBCs)</td>\n<td>300-350 ml</td>\n<td>RBCs</td>\n<td>\n<p>Hb by 1 g/dl</p>\n<p>Hematocrit by 3%</p>\n</td>\n<td>\n<p>1° to 6°C</p>\n</td>\n<td>\n<p>ACD/CPD-21 days, CPD-A-35 days, additive-42 days</p>\n</td>\n</tr>\n<tr>\n<td>Random donor platelets (RDP)</td>\n<td>50-70 ml</td>\n<td>Platelets</td>\n<td>platelet count by 5000-10,000/µL</td>\n<td rowspan=\"2\">20 to 24°C</td>\n<td rowspan=\"2\">5 days</td>\n</tr>\n<tr>\n<td>Single donor apheretic platelets (SDP*)</td>\n<td>200-400 ml</td>\n<td>Platelets</td>\n<td>platelet count by 30,000/µL</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma (FFP)</td>\n<td>200-250 ml</td>\n<td>Coagulation factors, protein C, protein S, anti thrombin</td>\n<td>coagulation factors by 2%</td>\n<td>-40 to -50°C</td>\n<td>1 year</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>10-15 ml</td>\n<td>fibrinogen, factor VIII, VWF</td>\n<td>80 IU Factor VIII</td>\n<td>-30 °C</td>\n<td>1 year</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1b1f01af443f48ec90792074de2e9c37x1280x1063.JPEG\" alt=\"Pearl Image\"><p>*SDP is obtained by collecting multiple units of platelets from a single donor using apheretic technology. </p>\n<p>1 SDP = 6 RDP</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/2e1d4838ba5448fcbfebeaa4b2a3ea0b.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8411",
      "difficulty": "medium"
    },
    {
      "text": "A 1-year-old child was brought to you with complaints of mucosal and joint bleeds. Laboratory investigation revealed the complete absence of  Von Willebrand factor (VWF) protein. What could be the most probable diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Type 1 Von Willebrand disease"
        },
        {
          "id": 2,
          "text": "Type 3 Von Willebrand disease"
        },
        {
          "id": 3,
          "text": "Type 2A Von Willebrand disease"
        },
        {
          "id": 4,
          "text": "Type 2B Von Willebrand disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\"><strong>Complete quantitative deficiency</strong> of vWF protein is seen in <strong>Type 3 Von Willebrand disease.</strong></p>\n<p class=\"p1\">von Willebrand disease (VWD) is the most common inherited bleeding disorder. Patients with VWD typically present with mucosal bleeding. VWD may be caused by quantitative or qualitative defects in VWF</p>\n<ul>\n<li>Type 1 VWD: Partial quantitative deficiency of vWF </li>\n<li>Type 2 VWD: Qualitative deficiency of vWF</li>\n<li>Type 3 VWD: Complete quantitative deficiency of vWF</li>\n</ul>\n<p>Note: </p>\n<ul>\n<li>Type 1 VWD is the most common type, accounting for 60-80% of all VWD patients.</li>\n<li>Most severe type is Type 3</li>\n<li>Most common inheritance: Autosomal dominant</li>\n</ul>\n<p>Characteristics of the subtypes of VWD are summarized below:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type</strong></td>\n<td><strong>Inheritance</strong></td>\n<td><strong>Mechanism</strong></td>\n<td><strong>Important characteristics</strong></td>\n</tr>\n<tr>\n<td>1</td>\n<td>AD</td>\n<td>Partial, quantitative deficiency of VWF</td>\n<td><strong>Most common type</strong></td>\n</tr>\n<tr>\n<td>3</td>\n<td>AR</td>\n<td>Complete quantitative deficiency</td>\n<td>Most severe VWD</td>\n</tr>\n<tr>\n<td>2A</td>\n<td>AD</td>\n<td>Loss of VWF multimers (increased cleavage by ADAMS13)</td>\n<td>Platelet adhesion defect</td>\n</tr>\n<tr>\n<td>2B</td>\n<td>AD</td>\n<td>Increased binding of VWF to platelets causing VWF-platelet complex destruction</td>\n<td><strong>Thrombocytopenia</strong></td>\n</tr>\n<tr>\n<td>2M</td>\n<td>AD</td>\n<td>Decreased affinity of VWF to platelets</td>\n<td>Platelet adhesion defect, very rare</td>\n</tr>\n<tr>\n<td>2N</td>\n<td><strong>AR</strong></td>\n<td>Decreased affinity of VWF to Factor VIII</td>\n<td><strong>Autosomal hemophilia</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>AD: autosomal dominant</p>\n<p>AR: autosomal recessive</p><hr><h3>Related Pearl: Platelet disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a852ed6ad094d22b4add695e1529e87x1280x1740.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Finding</strong></p>\n</td>\n<td>\n<p><strong>Bernard&ndash;Soulier syndrome</strong></p>\n</td>\n<td>\n<p><strong>Glanzmann&rsquo;s thrombasthenia</strong></p>\n</td>\n<td>\n<p><strong>von Willebrand Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Inheritance</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>Most common (type 1): Autosomal dominant</td>\n</tr>\n<tr>\n<td>&nbsp;Defect</td>\n<td>\n<p>Absence of Gp Ib-IX-V receptor</p>\n</td>\n<td>Absence of&nbsp;Gp IIb/IIIa receptor</td>\n<td>\n<p>Type 1: Partial quantitative deficiency of&nbsp;von Willebrand factor (VWF)</p>\n<p>Type 2: Qualitative defect of VWF</p>\n<p>Type 3: Complete quantitative deficiency of VWF&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Mechanism</td>\n<td>\n<p>Lack of Gp Ib-IX-V prevents platelet <strong>adhesion</strong> to VWF</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Platelets cannot <strong>aggregate</strong> as Gp IIb/IIIa normally binds&nbsp;fibrinogen and forms bridges between platelets&nbsp;</p>\n</td>\n<td>\n<p>There are 2 mechanisms:</p>\n<p>Platelet <strong>adhesion</strong> defect - due to absent vWF that normally binds to GPIB-IX and collagen in the subendothelium</p>\n<p>Factor VIII deficiency as&nbsp;vWF usually prevents its degradation</p>\n</td>\n</tr>\n<tr>\n<td>Platelet count&nbsp;</td>\n<td>Normal platelet count/ mild thrombocytopenia&nbsp;</td>\n<td>Normal</td>\n<td>Normal (except in type 2B- thrombocytopenia)</td>\n</tr>\n<tr>\n<td>Platelet morphology</td>\n<td>Large platelets/ megathrombocytes with dense granules</td>\n<td>Normal</td>\n<td>&nbsp;Normal/ large</td>\n</tr>\n<tr>\n<td>Bleeding time</td>\n<td>\n<p>Prolonged</p>\n</td>\n<td>Prolonged</td>\n<td>&nbsp;Prolonged</td>\n</tr>\n<tr>\n<td>Platelet aggregation tests (collagen, ADP, thrombin)</td>\n<td>Normal</td>\n<td>Abnormal</td>\n<td>&nbsp;Normal</td>\n</tr>\n<tr>\n<td>Ristocetin aggregation test</td>\n<td>\n<p>Abnormal (platelets does not aggregate)</p>\n<p>Does not normalize&nbsp;after addition of normal serum</p>\n</td>\n<td>\n<p>Normal</p>\n<p>(aggregation of platelets)</p>\n</td>\n<td>Abnormal, Normalizes after addition of normal serum</td>\n</tr>\n<tr>\n<td>VWF factor levels</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;Decreased</td>\n</tr>\n<tr>\n<td>PT/PTT</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;PT normal, aPTT prolonged</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7233",
      "difficulty": "medium"
    },
    {
      "text": "Romiplostim is a",
      "choices": [
        {
          "id": 1,
          "text": "Recombinant human erythropoietin"
        },
        {
          "id": 2,
          "text": "Recombinant human granulocyte colony-stimulating factor"
        },
        {
          "id": 3,
          "text": "Recombinant human IL-11"
        },
        {
          "id": 4,
          "text": "Thrombopoietin receptor agonist"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Romiplostim </strong>is a<strong>&nbsp;thrombopoietin receptor agonist</strong>. It is used in the management of immune thrombocytopenia (ITP).&nbsp;<strong>Eltrombopag</strong> is also a&nbsp;thrombopoietin receptor agonist. It is used in the treatment of ITP and severe aplastic anemia.</p>\n<p>Other options:</p>\n<p class=\"p1\">Option A- <strong>Epoetin alfa</strong> and <strong>darbepoetin alfa</strong> are&nbsp;<strong>recombinant human erythropoietin</strong>. They can be used in the treatment of <strong>anemias</strong> associated with surgery, AIDS, cancer chemotherapy, prematurity, and certain chronic inflammatory conditions.&nbsp;</p>\n<p class=\"p1\">Option B- <strong>Filgrastim</strong> is a <strong>recombinant&nbsp;granulocyte colony-stimulating factor.&nbsp;</strong>It increases neutrophil production. It is used in the treatment of <strong>neutropenia</strong>. Important adverse reactions include bone pain, local skin reaction, and cutaneous necrotizing vasculitis.</p>\n<p class=\"p1\">Option C- <strong>Oprelvekin</strong> is a recombinant <strong>human IL-11</strong>. It increases thrombopoiesis. It is used in the treatment of <strong>thrombocytopenia</strong> due to non-myeloid malignancies. Important adverse effects are&nbsp;fluid retention, tachycardia, palpitation, edema, and shortness of breath.</p>\n<p class=\"p1\"><strong>Sargramostim</strong> is a recombinant granulocyte-macrophage colony-stimulating factor. It stimulates <strong>myelopoiesis</strong>. Important adverse effects are&nbsp;bone pain, malaise, flu-like symptoms, diarrhea, dyspnea, and rash.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9166",
      "difficulty": "medium"
    },
    {
      "text": "A peripheral smear showed small sized platelets. This is characteristic of ____________",
      "choices": [
        {
          "id": 1,
          "text": "Wiskott Aldrich syndrome"
        },
        {
          "id": 2,
          "text": "Bernard soulier syndrome"
        },
        {
          "id": 3,
          "text": "ITP"
        },
        {
          "id": 4,
          "text": "Heparin induced thrombocytopenia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Small sized platelets on peripheral smear is a characteristic of Wiskott Aldrich syndrome.</p>\n<p><strong>Wiskott Aldrich syndrome: </strong>There is a<strong> mutation</strong>&nbsp;in the&nbsp;<strong>gene</strong>&nbsp;encoding Wiskott-Aldrich syndrome protein&nbsp;<strong>(WASP),</strong>&nbsp;which is located on&nbsp;<strong>Xp11.23</strong><strong>. The X-linked disease </strong>is&nbsp;characterized by <strong>thrombocytopenia, eczema</strong>, and a marked vulnerability to<strong>&nbsp;recurrent infection</strong>, resulting in early death.</p>\n<ul>\n<li><strong>Platelets</strong>&nbsp;are<strong>&nbsp;small</strong>&nbsp;in size.</li>\n<li>There is a progressive&nbsp;<strong>loss of T lymphocytes&nbsp;</strong>in the<strong>&nbsp;peripheral blood</strong>&nbsp;and in the<strong>&nbsp;T-cell zones (paracortical areas) of the lymph nodes,</strong>&nbsp;with variable defects in cellular immunity.</li>\n<li>Patients do not make antibodies to polysaccharide antigens, and the response to protein antigens is poor. They are prone&nbsp;to develop<strong>&nbsp;B-cell lymphomas.</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5820",
      "difficulty": "medium"
    },
    {
      "text": "A 20-year-old female patient presents with petechiae and one episode of epistaxis. She gives a history of an upper respiratory tract infection 3 weeks ago. Her lab reports are given below. Which of the following is the most appropriate management for this patient?<div class='question-desc-html'><p>Hemoglobin: 14 g/dL</p>\n<p>Platelet count: 12,000 cells/&mu;L</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Prednisolone"
        },
        {
          "id": 2,
          "text": "Platelet transfusion"
        },
        {
          "id": 3,
          "text": "Splenectomy"
        },
        {
          "id": 4,
          "text": "Amoxicillin-clavulanic acid"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario of a patient developing <strong>petechiae</strong> and one episode of <strong>epistaxis</strong> <strong>following upper respiratory tract infection</strong>, and lab reports showing a <strong>platelet count of 12,000/&mu;L</strong> are suggestive of <strong>immune thrombocytopenic purpura (ITP)</strong>. Since this patient has had only one episode of epistaxis and her hemoglobin is normal,<strong> </strong>the<strong> most appropriate management </strong>for this patient would be <strong>prednisolone.</strong></p>\n<p>In patients <strong>without significant bleeding</strong> and <strong>without severe thrombocytopenia</strong> (platelet count <strong>&lt; 5000 cells/&mu;L</strong>), the initial treatment is with <strong>glucocorticoids</strong> such as prednisolone or dexamethasone.</p>\n<p>If the patient has <strong>severe bleeding</strong> or <strong>severe thrombocytopenia</strong>, <strong>IVIg and glucocorticoids</strong> are used <strong>in</strong> <strong>conjunction</strong>. Anti-D is used as an alternative to IVIg, but is not preferred because of the risk of severe hemolytic reactions. <strong>Platelet transfusions</strong> (option B) are reserved <strong>for patients</strong> in whom there is a need to <strong>immediately raise the platelet counts</strong>.&nbsp;</p>\n<p>The decision to start treatment in a patient who is incidentally diagnosed and doesn't have any bleeding manifestations is based on the platelet count. Treatment is usually started for these patients if the platelet count is &lt; 30,000 cells/&mu;L.</p>\n<p><strong>Splenectomy</strong> (option C) has been used previously for patients who relapse after glucocorticoid therapy, but is now a <strong>reserved treatment option.</strong> In most adult patients, ITP resolves spontaneously, and so it is reasonable to observe the patient with intermittent treatment with IVIg before surgery is considered.</p>\n<p>Other drugs which are used in the treatment of ITP include <strong>anti-CD20 antibody rituximab</strong>, and <strong>thrombopoietin</strong> <strong>(TPO) receptor agonists</strong> such as <strong>romiplostim</strong> and <strong>eltrombopag</strong>.&nbsp;&nbsp;</p><hr><h3>Related Pearl: Idiopathic/Immune thrombocytopenic purpura (ITP)</h3><p>It is characterized by</p>\n<ul>\n<li>Isolated thrombocytopenia&mdash;the<strong>&nbsp;</strong>presence of antibody against platelet membrane glycoprotein and subsequent destruction in reticuloendothelial system</li>\n<li>Normal bone marrow&mdash;normal or even increased number of megakaryocytes</li>\n<li>Absence of other causes of thrombocytopenia.<strong>&nbsp;</strong></li>\n</ul>\n<p><strong>Types:</strong></p>\n<p>Acute (&lt;6 months) and chronic (&gt;6 months)<strong>&nbsp;</strong>idiopathic/immune thrombocytopenic purpura (ITP)</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p><strong>Acute ITP</strong></p>\n</td>\n<td>\n<p><strong>Chronic ITP</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Peak incidence</p>\n</td>\n<td>\n<p>2<strong>&ndash;</strong>6 years</p>\n</td>\n<td>\n<p>20<strong>&ndash;</strong>40 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sex predilection</p>\n</td>\n<td>\n<p><strong>None</strong></p>\n</td>\n<td>\n<p><strong>female: male ratio of 3:1&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antecedent infection</p>\n</td>\n<td>\n<p><strong>Common 1 to&nbsp;</strong><strong>3 weeks before</strong></p>\n</td>\n<td>\n<p><strong>Unusual</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Onset of bleeding</p>\n</td>\n<td>\n<p>Abrupt</p>\n</td>\n<td>\n<p>Insidious</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Platelet count</p>\n</td>\n<td>\n<p>&lt;20000/microlitre</p>\n</td>\n<td>\n<p>30<strong>&ndash;</strong>80000/microlitre</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Eosinophilia/lymphocytosis</p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Duration</p>\n</td>\n<td>\n<p>2<strong>&ndash;</strong>6 weeks</p>\n</td>\n<td>\n<p>Months or years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Spontaneous remission</strong></p>\n</td>\n<td>\n<p><strong>80% of cases</strong></p>\n</td>\n<td>\n<p><strong>Uncommon</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2929",
      "difficulty": "medium"
    },
    {
      "text": "A girl presented to the casualty with anuria for 2 days and a recent history of fever and bloody diarrhea 5 days back. An examination reveals petechiae on the trunk and jaundice of the skin, but no neurological deficit. Schistocytes are seen on a peripheral smear and other lab findings are shown below. Besides supportive care, what is the best step in management?\n<div class='question-desc-html'><ul>\n<li>Hemoglobin: 8.6 g/dL</li>\n<li>Leukocyte count: 12,000/mm³</li>\n<li>Platelet count: 32,000/mm³</li>\n<li>Serum Blood urea nitrogen:48 mg/dL</li>\n<li>Creatinine: 2.7 mg/dL</li>\n<li>S. Potassium 6.2</li>\n<li>ABG: pH=7.06</li>\n</ul></div>",
      "choices": [
        {
          "id": 1,
          "text": "Platelet transfusion"
        },
        {
          "id": 2,
          "text": "PRBC transfusion"
        },
        {
          "id": 3,
          "text": "Hemodialysis"
        },
        {
          "id": 4,
          "text": "IV Antibiotics"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario of this child, along with lab investigations suggests a diagnosis of <strong>hemolytic uremic syndrome</strong> (HUS) causing <strong>AKI</strong> resulting in<strong> acidosis</strong> and <strong>hyperkalemia</strong>. Thus the patient should be managed with <strong>hemodialysis.</strong></p>\n<p>Up to half of the patients with HUS may require <strong>dialysis</strong> support during the <strong>acute phase </strong>of the disease. The patient’s symptoms <strong>(anuria)</strong> and lab findings <strong>(acidosis, hyperkalemia)</strong> align with the indications for dialysis in AKI. Indications include:</p>\n<ol>\n<li>Anuria/oliguria</li>\n<li>Severe metabolic acidosis</li>\n<li>Hyperkalemia</li>\n<li>Uremic symptoms, such as pericarditis or encephalopathy</li>\n<li>Fluid overload unresponsive to diuretics</li>\n</ol>\n<p><strong>HUS </strong>is a condition characterized by <strong>microangiopathic hemolytic anemia</strong>, <strong>thrombocytopenia</strong>, and <strong>acute kidney injury</strong>. It commonly affects children up to <strong>5 years</strong> of age. The disease is often linked to a preceding gastrointestinal infection caused by <strong>Shiga toxin-producing</strong> strains like <strong>E. coli O157:H7</strong> or <strong>Shigella dysenteriae</strong>.</p>\n<p>There is widespread injury to small vessel <strong>endothelium</strong>, leading to <strong>thrombotic microangiopathy</strong>. The formation of these <strong>microthrombi </strong>causes a decrease in platelet count. There is associated destruction of RBCs causing <strong>hemolytic anemia</strong>. Renal vascular occlusion by microthrombi results in <strong>acute kidney injury</strong>.</p>\n<p>Investigations will show a hemolytic blood picture with reticulocytosis and <strong>schistocytes</strong> on a peripheral smear. There will be<strong> reduced platelets </strong>and <strong>deranged renal function tests</strong>. Liver function tests will reveal an <strong>elevated indirect bilirubin</strong>.</p>\n<p>Other options</p>\n<p>Option A:<strong> Platelet transfusions</strong> are generally<strong> not recommended </strong>in HUS unless there is active bleeding because ongoing microangiopathic processes rapidly consume platelets and transfusions may exacerbate the condition.</p>\n<p>Option B The patient's hemoglobin is 8.6 g/dL, which is mildly low. However, <strong>RBC transfusion</strong> is generally reserved for more severe anemia with <strong>Hb&lt;7g/dL</strong>.</p>\n<p>Option D. <strong>Antibiotics</strong> are <strong>ineffective</strong> in treating HUS and may worsen the hemolysis and stimulate the release of <strong>Shiga toxin</strong>.</p><hr><h3>Related Pearl: Differences between TTP and HUS</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p><strong>TTP</strong></p>\n</td>\n<td>\n<p><strong>HUS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Causative agent</p>\n</td>\n<td>\n<p>A deficiency of, or antibodies to the metalloprotease ADAMTS13</p>\n</td>\n<td>\n<p>E. coli (O157: H7)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GI prodrome</p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Age group affected</p>\n</td>\n<td>\n<p>Adults</p>\n</td>\n<td>\n<p>Children</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sex affected</p>\n</td>\n<td>\n<p>Females</p>\n</td>\n<td>\n<p>No sex predilection</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Relapses</p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Renal impairment</p>\n</td>\n<td>\n<p>Usually mild</p>\n</td>\n<td>\n<p>Often severe</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Severe thrombocytopenia</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Pentad of TTP and triad of HUS</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f1004c9ccec548288509c1eaed783d3fx1280x1840.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6462",
      "difficulty": "medium"
    },
    {
      "text": "Patients with protein C deficiency are at an increased risk of developing all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "Deep vein thrombosis"
        },
        {
          "id": 2,
          "text": "Purpura fulminans"
        },
        {
          "id": 3,
          "text": "Warfarin-induced skin necrosis"
        },
        {
          "id": 4,
          "text": "Spontaneous bleeding"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Spontaneous bleeding is not seen in protein C deficiency. It is characterised by an&nbsp;<strong>increased </strong>tendency for <strong>thrombus formation</strong>.</p>\n<p><strong>Protein C deficiency</strong> is a rare genetic disorder.&nbsp;It predisposes to the following thrombotic complications:</p>\n<ul>\n<li><strong>Deep vein thrombosis </strong>(DVT):\n<ul>\n<li>Adults with a mild form of the disease at higher risk of developing venous thromboembolism.</li>\n</ul>\n</li>\n<li><strong>Purpura fulminans</strong>:\n<ul>\n<li>Severe form of <strong>DIC</strong></li>\n<li>Thrombosis of extensive areas of the skin</li>\n<li>Affects predominantly young children following viral or bacterial infection.&nbsp;</li>\n</ul>\n</li>\n<li><strong>Warfarin-induced skin necrosis:</strong>\n<ul>\n<li>Rare complication seen in patients with congenital or acquired deficiencies of protein C or S.</li>\n<li>Thrombosis of the skin leads to well-demarcated erythematous lesions with central necrosis on the thighs, buttocks, breasts, or toes(shown below).</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6ad8b3fbe45c4161a1887693df8a08aex416x501.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1754",
      "difficulty": "medium"
    },
    {
      "text": "A 4-year-old girl presented with a history of easy bruising and frequent nosebleeds. There was no history of fever. The platelet count was low and the peripheral smear showed platelets, as marked by the arrows. Platelet function studies show an absence of aggregation to ristocetin but a normal response to adenosine diphosphate (ADP), epinephrine, and collagen. What is the likely diagnosis?<div class='question-desc-html'><p>aPTT: Normal<br />Bleeding time: prolonged<br />Serum creatinine and urea within normal limits</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Glanzmann thrombasthenia"
        },
        {
          "id": 2,
          "text": "Thrombotic thrombocytopenic purpura"
        },
        {
          "id": 3,
          "text": "von Willebrand disease"
        },
        {
          "id": 4,
          "text": "Bernard-Soulier syndrome"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The clinical scenario is suggestive of&nbsp;<strong>Bernard-Soulier syndrome.</strong></p>\n<p>Points that favor the diagnosis:</p>\n<ul>\n<li>History of<strong> easy bruising</strong> and <strong>frequent nosebleeds</strong></li>\n<li><strong>Low&nbsp;platelet count&nbsp;</strong>and <strong>giant</strong> platelets</li>\n<li><strong>Prolonged bleeding time</strong></li>\n<li><strong>Absent aggregation </strong>to<strong> ristocetin</strong> in platelet function studies&nbsp;</li>\n</ul>\n<p>It is an <strong>autosomal recessive </strong>disorder due to an inherited deficiency of platelet membrane <strong>glycoprotein</strong> complex <strong>Ib-IX</strong>. This glycoprotein is a receptor of the von Willebrand factor, which is needed for normal platelet adhesion to the subendothelial extracellular matrix.&nbsp;</p>\n<p>They mostly present with easy bruising, nose bleeds, mucosal bleeding, menorrhagia, and occasionally gastrointestinal bleeding.</p>\n<p><strong>Laboratory features</strong>:</p>\n<ul>\n<li>Low platelet count</li>\n<li>Large platelets on smear</li>\n<li>Platelet&nbsp;aggregation will not occur in response to ristocetin but have normal aggregation with&nbsp; ADP, collagen, or epinephrine</li>\n<li>Platelet membrane glycoprotein abnormality is seen on flow cytometry.</li>\n</ul>\n<p>Supportive treatment is only needed. Antiplatelet medications like aspirin should be avoided. Anti-fibrinolytic can be used in mucosal bleeding.</p>\n<p>The below image shows giant platelets in peripheral blood smear in&nbsp;Bernard-Soulier syndrome.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a9b03eb479d840ff8c169ee91bd4f1aex816x612.PNG\" alt=\"Explanation Image\"><p>Other options:</p>\n<p>Option A-&nbsp;<strong>Glanzmann thrombasthenia</strong> is an <strong>autosomal recessive</strong> platelet disorder that results from a deficiency of the <strong>glycoprotein IIb/IIIa</strong> complex.</p>\n<p>Patients mainly present with petechiae, ecchymosis, excessive bleeding after dental extraction, menorrhagia, gingival bleeding, and epistaxis.&nbsp;</p>\n<p>Laboratory features:</p>\n<ul>\n<li><strong>Normal platelet count</strong></li>\n<li>Bleeding time- prolonged</li>\n<li><strong>Normal platelet morphology</strong> on peripheral smear</li>\n<li>Platelet&nbsp;aggregation responses to&nbsp;ADP, collagen, or epinephrine are low but <strong>have normal aggregation with&nbsp;ristocetin</strong></li>\n<li>Flow cytometry and monoclonal antibodies confirm the diagnosis</li>\n</ul>\n<p>Option B-&nbsp;&nbsp;<strong>Thrombotic thrombocytopenic purpura</strong>&nbsp;is due to the deficiency of <strong>ADAMTS13,</strong> which is the <strong>negative regulator </strong>of<strong> von Willebrand factor (vWF)</strong>. They are mostly seen in adults less than 40 years of age.</p>\n<p>They are classically manifested by a pentad of:</p>\n<ul>\n<li>Fever</li>\n<li>Neurological abnormalities</li>\n<li>Microangiopathic hemolytic anemia</li>\n<li>Thrombocytopenia</li>\n<li>Renal failure</li>\n</ul>\n<p>Option C-&nbsp;<strong>von Willebrand disease</strong> is a common inherited disorder caused by <strong>deficiency</strong> or dysfunction of the vWF.&nbsp;Patients will have thrombocytopenia with mild to moderate mucocutaneous hemorrhage.</p>\n<p>Laboratory features:</p>\n<ul>\n<li>Mild thrombocytopenia</li>\n<li>Slightly enlarged platelets</li>\n<li>Decreased levels of&nbsp;von Willebrand factor</li>\n<li>Low levels of <strong>ristocetin&nbsp;</strong>cofactor</li>\n<li><strong>Prolonged </strong>activated partial thromboplastin time (<strong>aPTT</strong>)and <strong>bleeding time</strong></li>\n</ul><hr><h3>Related Pearl: Platelet disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a852ed6ad094d22b4add695e1529e87x1280x1740.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Finding</strong></p>\n</td>\n<td>\n<p><strong>Bernard&ndash;Soulier syndrome</strong></p>\n</td>\n<td>\n<p><strong>Glanzmann&rsquo;s thrombasthenia</strong></p>\n</td>\n<td>\n<p><strong>von Willebrand Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Inheritance</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>Most common (type 1): Autosomal dominant</td>\n</tr>\n<tr>\n<td>&nbsp;Defect</td>\n<td>\n<p>Absence of Gp Ib-IX-V receptor</p>\n</td>\n<td>Absence of&nbsp;Gp IIb/IIIa receptor</td>\n<td>\n<p>Type 1: Partial quantitative deficiency of&nbsp;von Willebrand factor (VWF)</p>\n<p>Type 2: Qualitative defect of VWF</p>\n<p>Type 3: Complete quantitative deficiency of VWF&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Mechanism</td>\n<td>\n<p>Lack of Gp Ib-IX-V prevents platelet <strong>adhesion</strong> to VWF</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Platelets cannot <strong>aggregate</strong> as Gp IIb/IIIa normally binds&nbsp;fibrinogen and forms bridges between platelets&nbsp;</p>\n</td>\n<td>\n<p>There are 2 mechanisms:</p>\n<p>Platelet <strong>adhesion</strong> defect - due to absent vWF that normally binds to GPIB-IX and collagen in the subendothelium</p>\n<p>Factor VIII deficiency as&nbsp;vWF usually prevents its degradation</p>\n</td>\n</tr>\n<tr>\n<td>Platelet count&nbsp;</td>\n<td>Normal platelet count/ mild thrombocytopenia&nbsp;</td>\n<td>Normal</td>\n<td>Normal (except in type 2B- thrombocytopenia)</td>\n</tr>\n<tr>\n<td>Platelet morphology</td>\n<td>Large platelets/ megathrombocytes with dense granules</td>\n<td>Normal</td>\n<td>&nbsp;Normal/ large</td>\n</tr>\n<tr>\n<td>Bleeding time</td>\n<td>\n<p>Prolonged</p>\n</td>\n<td>Prolonged</td>\n<td>&nbsp;Prolonged</td>\n</tr>\n<tr>\n<td>Platelet aggregation tests (collagen, ADP, thrombin)</td>\n<td>Normal</td>\n<td>Abnormal</td>\n<td>&nbsp;Normal</td>\n</tr>\n<tr>\n<td>Ristocetin aggregation test</td>\n<td>\n<p>Abnormal (platelets does not aggregate)</p>\n<p>Does not normalize&nbsp;after addition of normal serum</p>\n</td>\n<td>\n<p>Normal</p>\n<p>(aggregation of platelets)</p>\n</td>\n<td>Abnormal, Normalizes after addition of normal serum</td>\n</tr>\n<tr>\n<td>VWF factor levels</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;Decreased</td>\n</tr>\n<tr>\n<td>PT/PTT</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;PT normal, aPTT prolonged</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/0766850a9c0d40918b5e00be402c1875.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2826",
      "difficulty": "medium"
    },
    {
      "text": " Match the Tests used to assess the Coagulation pathway with their use.<div class='question-desc-html'><p> </p>\n<table>\n<tbody>\n<tr>\n<td>Test</td>\n<td>Use</td>\n</tr>\n<tr>\n<td><br />1. Prothrombin Time (PT)</td>\n<td>a. Evaluates the ability of platelets to form a hemostatic plug</td>\n</tr>\n<tr>\n<td>2. Activated partial thromboplastin time (aPTT)</td>\n<td>b. Evaluates the extrinsic and the common coagulation pathways</td>\n</tr>\n<tr>\n<td>3. Thrombin time (TT)</td>\n<td>c. Evaluates the intrinsic and the common coagulation pathways.</td>\n</tr>\n<tr>\n<td>4. Bleeding time (BT)</td>\n<td>d. Evaluate the conversion of fibrinogen into fibrin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-b, 2-c, 3-d, 4-a "
        },
        {
          "id": 2,
          "text": "1-c, 2-d, 3-a, 4-b "
        },
        {
          "id": 3,
          "text": " 1-a, 2-c, 3-b, 4-d "
        },
        {
          "id": 4,
          "text": " 1-d, 2-b, 3-c, 4-a"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The correctly matched order of the <strong>tests</strong> used to assess the <strong>Coagulation pathway</strong> with their use is  <strong>1-b, 2-c, 3-d, 4-a </strong>(Option A)</p>\n<table>\n<tbody>\n<tr>\n<td>Test</td>\n<td>Use</td>\n</tr>\n<tr>\n<td>1. <strong>Prothrombin Time</strong> (PT)</td>\n<td>b. Evaluates the <strong>extrinsic</strong> and the <strong>common</strong> coagulation pathways.</td>\n</tr>\n<tr>\n<td>2.<strong> Activated partial thromboplastin</strong> time (aPTT)</td>\n<td>c. Evaluates the <strong>intrinsic</strong> and the <strong>common</strong> coagulation pathways.</td>\n</tr>\n<tr>\n<td>3.<strong> Thrombin</strong> time (TT)</td>\n<td><br />d. Evaluate the conversion of <strong>fibrinogen </strong>into <strong>fibrin</strong>.</td>\n</tr>\n<tr>\n<td>4. <strong>Bleeding </strong>time (BT)</td>\n<td><br />a. Evaluate the ability of <strong>platelets</strong> to form a <strong>hemostatic plug. </strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>1) <strong>Prothrombin </strong>time<strong> </strong>is the time taken for citrated plasma to clot after the addition of tissue thromboplastin and calcium. It evaluates the <strong>extrinsic</strong> pathway and <strong>common</strong> pathways, i.e., factors <strong>VII, X, V, II </strong>(prothrombin), and <strong>fibrinogen</strong>. Normal PT is<strong> </strong>11 to 16 seconds. Causes of prolonged PT include<strong> </strong>Liver diseases,<strong> Vitamin K deficiency</strong>, Disseminated intravascular coagulation (<strong>DIC</strong>), Factor VII, X, V, or prothrombin deficiency.</p>\n<p>2) <strong>Activated partial thromboplastin </strong>time (APTT) is the time taken for citrated plasma to clot in the presence of a surface activator (kaolin), phospholipid, and<strong> </strong>calcium. It evaluates <strong>intrinsic</strong> and <strong>common</strong> pathways, i.e., factors<strong> VIII, IX,</strong> X, XI, XII, V, II, and fibrinogen. Normal APTT is 30 to 40 seconds. APTT is<strong> </strong>prolonged in <strong>Hemophilias</strong> that involve deficiencies of factor VIII, IX or XI, DIC, Liver diseases, etc.</p>\n<p>3) <strong>Bleeding Time</strong> (BT) is used as a screening test for disorders of platelet-vessel wall interactions. It measures the time required for bleeding to stop after a standardized superficial cut<strong> </strong>of the skin capillary bed. It assesses<strong> platelet number</strong> and<strong> function</strong>. The normal BT is 2-8 minutes. Prolonged bleeding time is found in <strong>thrombocytopenia</strong> and <strong>Von Willebrand disease</strong>.</p>\n<p>4) <strong>Thrombin Time </strong>(TT) assesses the effectiveness of the <strong>final step</strong> of coagulation in which<strong> fibrinogen</strong> is converted to <strong>fibrin</strong>. Thrombin is added to the plasma along with calcium, and clotting time is determined. The normal value of TT is 15 to 19 seconds. Prolonged TT is seen in conditions with <strong>decreased fibrinogen</strong> concentration, like <strong>DIC</strong> and <strong>afibrinogenemia</strong>.</p>\n<p>5) <strong>Clotting</strong> <strong>time</strong> measures the time taken for the <strong>fresh blood</strong> to <strong>clot</strong>. Normal: 3–6 minutes. It is one of the oldest tests and is <strong>not sensitive </strong>as it fails to detect mild/ moderate coagulant defects. Hence, it is not preferred as a screening test. It is prolonged in severe deficiency of <strong>factor VIII, IX</strong>, or fibrinogen (afibrinogenemia) and in heparin therapy</p><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><hr><h3>Related Pearl: Parameters of the coagulation pathway and its uses</h3><p><strong> Parameters of the coagulation pathway and its uses</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Parameter </strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>Prothrombin Time (PT)</td>\n<td>It is used to monitor the functioning of the extrinsic and the common coagulation pathways. Normal PT is 11–13 seconds.</td>\n</tr>\n<tr>\n<td>Activated partial thromboplastin time (aPTT)</td>\n<td>It is used to monitor the functioning of the intrinsic and the common coagulation pathways. Normal aPTT is 25–35 seconds. A relatively rare cause of prolonged aPTT is the presence of antibodies against coagulation plasma proteins called inhibitors. It can be seen due to the following reasons: Hemophilia A and B patients receiving clotting factors to control their bleeding episodes, Pregnancy, Autoimmune diseases, Malignancies (lymphoma, prostate cancer), and Dermatologic conditions.</td>\n</tr>\n<tr>\n<td>Thrombin time (TT)</td>\n<td>It is used for testing the conversion of fibrinogen into fibrin and depends on adequate fibrinogen levels. </td>\n</tr>\n<tr>\n<td>Bleeding time (BT)</td>\n<td>It is the time taken for a standardized skin puncture to stop bleeding. It tests the ability of blood vessels to constrict and platelets to form a hemostatic plug. </td>\n</tr>\n<tr>\n<td>Fibrin degradation products (FDPs)</td>\n<td>They are used to assess the fibrinolytic activity, and they are increased in disseminated intravascular coagulation (DIC). </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG1867",
      "difficulty": "easy"
    },
    {
      "text": "A 24-year-old female patient presents with jaundice, confusion, and aphasia. Peripheral smear shows the presence of schistocytes. Coagulation studies were found to be normal but platelet count is decreased. Serum haptoglobin levels are low. Which of the following is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Immune thrombocytopenic purpura"
        },
        {
          "id": 2,
          "text": "Disseminated intravascular coagulation"
        },
        {
          "id": 3,
          "text": "Hemolytic uremic syndrome"
        },
        {
          "id": 4,
          "text": "Thrombotic thrombocytopenic purpura"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The most likely diagnosis in this case is<strong>&nbsp;thrombotic thrombocytopenic purpura (TTP)</strong>.</p>\n<p><strong>Thrombotic thrombocytopenic purpura (TTP) </strong>is&nbsp;<strong>thrombotic microangiopathy</strong> that can be inherited or spontaneously acquired. It results from a <strong>deficiency of</strong>&nbsp;the metalloprotease <strong>ADAMTS13,&nbsp;</strong>which&nbsp;normally <strong>cleaves multimers</strong> of<strong>&nbsp;vWF</strong>. <strong>Failure to cleave</strong> these multimers results in <strong>excessive platelet adhesion </strong>and<strong> aggregation</strong>. This causes&nbsp;platelet thrombi and fibrin deposits to form at various sites in the circulation. These thrombi result in the <strong>classic pentad</strong> of clinical features:&nbsp;</p>\n<ul>\n<li>Microangiopathic hemolytic anemia (MAHA)</li>\n<li>Thrombocytopenia</li>\n<li>Renal failure</li>\n<li>Neurologic findings</li>\n<li>Fever</li>\n</ul>\n<p>The <strong>platelet thrombi narrow</strong> the vessel <strong>lumen,</strong>&nbsp;causing&nbsp;<strong>shearing stress</strong> on the red blood cells that are passing through. This results in microangiopathic hemolytic anemia. The same <strong>platelet thrombi&nbsp;</strong>cause <strong>microvascular occlusion</strong> and result in features like<strong> renal failure</strong> and <strong>neurological manifestations</strong>. On <strong>peripheral smear</strong>, these fragmented red cells appear as <strong>schistocytes</strong> or <strong>helmet cells,</strong> as shown in the image below:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7698db7a0b9c479d9e61b2dc0d1b4fd4x754x594.PNG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>MAHA is an example of<strong> intravascular hemolysis</strong>. It causes an <strong>increase</strong> in <strong>free hemoglobin</strong> in the blood, which is <strong>taken up by haptoglobin</strong>. This <strong>reduces free haptoglobin</strong> in the blood. Moreover, the activation of the coagulation cascade is not of primary importance in TTP and HUS, and hence the <strong>coagulation studies are usually normal</strong>. The mainstay of <strong>treatment</strong> of TTP is <strong>therapeutic plasma exchange</strong>.</p>\n<p>Other causes of microangiopathic hemolytic anemia include:</p>\n<ul>\n<li>Disseminated intravascular coagulation (DIC) (Most common)</li>\n<li>Hemolytic uremic syndrome (HUS)</li>\n<li>Malignant hypertension</li>\n<li>Systemic lupus erythematosus</li>\n<li>Disseminated cancer&nbsp;</li>\n</ul>\n<p>Other options:</p>\n<p>Option A: <strong>Immune thrombocytopenic purpura</strong> occurs as a <strong>chronic</strong> <strong>disease</strong> in adults with several episodes over time, usually <strong>following infections</strong>.&nbsp;It presents as mucocutaneous bleeding and very low platelet counts. These patients have abnormally l<strong>arge platelets (megathrobocytes)</strong> in the peripheral smear, which is a sign of accelerated thrombopoiesis. <strong>Coagulation</strong> <strong>studies</strong> are <strong>normal</strong>.&nbsp;</p>\n<p>Option B:<strong> Disseminated intravascular coagulation&nbsp;</strong>refers to the<strong> widespread intravascular clot formation</strong>, commonly due to sepsis, trauma, and obstetric complications. These patients present with petechiae, ecchymoses, and&nbsp;<strong>oozing from venipuncture sites.</strong>&nbsp;They do not display the classic pentad seen in TTP. Schistocytes may be present on peripheral smears. <strong>Deranged clotting parameters</strong> are seen and <strong>fibrin degradation products</strong> such as D-dimers are <strong>elevated</strong>.</p>\n<p>Option C: <strong>Hemolytic uremic syndrome</strong> is a disorder seen predominantly in <strong>children</strong>, following an episode of <strong>bloody diarrhea</strong>. <strong><em>Escherichia coli</em> O157:H7</strong> is most commonly the cause of this diarrhea. It can also present with&nbsp;acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia, but <strong>neurological manifestations are less common</strong>.</p><hr><h3>Related Pearl: Differences between TTP and HUS</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p><strong>TTP</strong></p>\n</td>\n<td>\n<p><strong>HUS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Causative agent</p>\n</td>\n<td>\n<p>A deficiency of, or antibodies to the metalloprotease ADAMTS13</p>\n</td>\n<td>\n<p>E. coli (O157: H7)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GI prodrome</p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Age group affected</p>\n</td>\n<td>\n<p>Adults</p>\n</td>\n<td>\n<p>Children</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sex affected</p>\n</td>\n<td>\n<p>Females</p>\n</td>\n<td>\n<p>No sex predilection</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Relapses</p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Renal impairment</p>\n</td>\n<td>\n<p>Usually mild</p>\n</td>\n<td>\n<p>Often severe</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Severe thrombocytopenia</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Pentad of TTP and triad of HUS</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f1004c9ccec548288509c1eaed783d3fx1280x1840.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Indications of Plasma exchange Therapy</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Speciality</strong></p>\n</td>\n<td>\n<p><strong>Condition</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neurology</p>\n</td>\n<td>\n<p>Acute Guillain Barre syndrome</p>\n<p>Chronic inflammatory demyelinating polyneuropathy</p>\n<p>Myasthenia gravis</p>\n<p>Polyneuropathy associated with paraproteinaemias</p>\n<p>PANDAS</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hematology</p>\n</td>\n<td>\n<p>Thrombotic thrombocytopenic purpura</p>\n<p>Atypical hemolytic-uraemic syndrome</p>\n<p>Hyperviscosity syndromes</p>\n<p>Severe/symptomatic cryoglobulinemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Renal</p>\n</td>\n<td>\n<p>Goodpasture&rsquo;s syndrome</p>\n<p>Antineutrophil cytoplasmic antibody (ANCA)-associated rapidly progressive glomerulonephritis</p>\n<p>Recurrent focal segmental glomerular sclerosis</p>\n<p>Antibody-mediated renal transplant rejection</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Metabolic</p>\n</td>\n<td>\n<p>Familial hypercholesterolemia</p>\n<p>Fulminant Wilson&rsquo;s disease</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9138",
      "difficulty": "medium"
    },
    {
      "text": "A patient undergoing a pre-op evaluation has an isolated prolonged aPTT. Further investigations show deficient levels of factor XII but he has no history of spontaneous bleeding. Which of the following is the best way to manage this patient?<div class='question-desc-html'><p>aPTT: activated partial thromboplastin time</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Give Factor XII concentrate before surgery"
        },
        {
          "id": 2,
          "text": "Transfuse cryoprecipitate before surgery"
        },
        {
          "id": 3,
          "text": "Proceed with surgery without any treatment"
        },
        {
          "id": 4,
          "text": "Transfuse fresh frozen plasma before surgery"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The most appropriate management for this patient is to<strong> proceed with surgery without additional treatment.</strong></p>\n<p><strong>Factor XII deficiency</strong> leads to a <strong>prolonged</strong> <strong>activated partial thromboplastin time </strong>(APTT) in <strong>vitro</strong>, but it does not increase the risk of<strong> bleeding</strong> in <strong>vivo</strong>. This discrepancy is due to the role of<strong> factor XII</strong> in the <strong>intrinsic pathway of coagulation</strong>, which does not significantly impact hemostasis in vivo. Patients with Factor XII deficiency typically do not exhibit hemorrhagic symptoms and thus will have<strong> normal hemostasis</strong> during surgical procedures.</p><hr><h3>Related Pearl: Blood components</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Volume     (1 unit)</strong></td>\n<td><strong>Content</strong></td>\n<td><strong>Clinical response, increase in </strong></td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>Shelf-life</strong></td>\n</tr>\n<tr>\n<td>Whole blood</td>\n<td>450 ml</td>\n<td>RBCs, platelets, plasma</td>\n<td>Hb and plasma volume</td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>Packed red blood cells (PRBCs)</td>\n<td>300-350 ml</td>\n<td>RBCs</td>\n<td>\n<p>Hb by 1 g/dl</p>\n<p>Hematocrit by 3%</p>\n</td>\n<td>\n<p>1° to 6°C</p>\n</td>\n<td>\n<p>ACD/CPD-21 days, CPD-A-35 days, additive-42 days</p>\n</td>\n</tr>\n<tr>\n<td>Random donor platelets (RDP)</td>\n<td>50-70 ml</td>\n<td>Platelets</td>\n<td>platelet count by 5000-10,000/µL</td>\n<td rowspan=\"2\">20 to 24°C</td>\n<td rowspan=\"2\">5 days</td>\n</tr>\n<tr>\n<td>Single donor apheretic platelets (SDP*)</td>\n<td>200-400 ml</td>\n<td>Platelets</td>\n<td>platelet count by 30,000/µL</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma (FFP)</td>\n<td>200-250 ml</td>\n<td>Coagulation factors, protein C, protein S, anti thrombin</td>\n<td>coagulation factors by 2%</td>\n<td>-40 to -50°C</td>\n<td>1 year</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>10-15 ml</td>\n<td>fibrinogen, factor VIII, VWF</td>\n<td>80 IU Factor VIII</td>\n<td>-30 °C</td>\n<td>1 year</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1b1f01af443f48ec90792074de2e9c37x1280x1063.JPEG\" alt=\"Pearl Image\"><p>*SDP is obtained by collecting multiple units of platelets from a single donor using apheretic technology. </p>\n<p>1 SDP = 6 RDP</p><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6458",
      "difficulty": "hard"
    },
    {
      "text": " A young woman in the casualty with right leg pain, swelling, and erythema is diagnosed with a DVT. She had a pulmonary embolism six months ago and was treated with warfarin, which was recently stopped. Coagulation assays show insensitivity to activated protein C. What is the likely finding upon further evaluation?<div class='question-desc-html'><p>DVT: Deep Vein Thrombosis</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Elevated homocysteine"
        },
        {
          "id": 2,
          "text": "Factor V mutation"
        },
        {
          "id": 3,
          "text": "Prothrombin mutation"
        },
        {
          "id": 4,
          "text": "Antithrombin III deficiency"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The patient’s presentation of <strong>DVT </strong>and history of<strong> pulmonary embolism</strong>, along with <strong>insensitivity to activated protein C</strong>, strongly suggests a <strong>Factor V Leiden</strong> mutation.</p>\n<p>The mutation occurs in the <strong>Factor V gene</strong> and leads to the production of a Factor V protein that is resistant to inactivation by <strong>activated protein C</strong> (APC). Normally, APC degrades Factor V to prevent excessive clotting, but in individuals with Factor V Leiden, this process is impaired, leading to a higher risk of forming abnormal blood clots.</p>\n<p>Factor V Leiden mutation is the most common<strong> inherited thrombophilia</strong>, which follows an <strong>autosomal dominant</strong> inheritance pattern. <strong>Heterozygous </strong>carriers have a 3 to 8 times increased risk of venous thromboembolism (VTE), while <strong>homozygous</strong> individuals have a significantly higher risk, approximately 50 to 100 times greater.</p>\n<p>Patients with Factor V Leiden are at increased risk for conditions like<strong> deep vein thrombosis</strong> (DVT) and <strong>pulmonary embolism</strong> (PE). The risk is further elevated in situations such as<strong> pregnancy</strong>, <strong>oral contraceptive use</strong>, and<strong> prolonged immobilization</strong>.</p>\n<p>The diagnosis is typically confirmed through <strong>genetic testing</strong> for the Factor V Leiden mutation. <strong>Coagulation assays</strong> showing <strong>APC resistance </strong>are also indicative of this condition.</p>\n<p>Management of patients with Factor V Leiden involves <strong>anticoagulation</strong> therapy during episodes of thrombosis. <strong>Long-term anticoagulation</strong> may be considered in patients with<strong> recurrent thrombotic</strong> events or significant <strong>risk factors</strong>. Preventive measures are crucial for high-risk situations to reduce the likelihood of thromboembolic events.</p>\n<p>Other options:</p>\n<p>Option A: While elevated <strong>homocysteine </strong>can increase the risk of thrombosis, it does not cause APC resistance.</p>\n<p>Option C: The <strong>prothrombin gene mutation (G20210A)</strong> increases <strong>prothrombin levels</strong>, leading to a higher risk of clotting, but it does not involve APC resistance.</p>\n<p>Option D: This condition leads to reduced inhibition of <strong>thrombin</strong> and other clotting factors, increasing clotting risk, but it is not associated with APC resistance.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6477",
      "difficulty": "medium"
    },
    {
      "text": "A woman presents with episodic nose and gum bleeding over the past two weeks. She is not on any medications. Examination reveals a hemoglobin level of 13.1 g/dL, a leukocyte count of 6600/mm³, a platelet count of 28,000/mm³, and a normal coagulation profile. A peripheral smear shows normal-sized platelets with no abnormal cells. Which diagnostic test is indicated for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "ADAMTS 13 testing"
        },
        {
          "id": 2,
          "text": "Hepatitis C Serology"
        },
        {
          "id": 3,
          "text": "Bone marrow biopsy"
        },
        {
          "id": 4,
          "text": "Anti PF-4 antibodies"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This clinical scenario with isolated thrombocytopenia suggests<strong> immune thrombocytopenic purpura</strong> (ITP). <strong>Hepatitis C serology</strong> is essential to rule out <strong>secondary causes </strong>in suspected ITP patients thus <strong>HCV serology</strong> is indicated.</p>\n<p>In patients suspected of having <strong> Immune Thrombocytopenic Purpura (ITP)</strong>, secondary causes such as <strong>infections</strong> should be ruled out.<strong> Hepatitis C</strong> and <strong>HIV serology</strong> should be obtained in adults with suspected primary immune thrombocytopenia, as treating these infections is likely to improve <strong>thrombocytopenia</strong>.</p>\n<p><strong>Immune Thrombocytopenic Purpura</strong> (ITP) is an acquired disorder characterized by immune-mediated destruction of platelets and inhibition of platelet release from megakaryocytes. It can be<strong> primary (idiopathic)</strong> or<strong> secondary</strong> to underlying conditions such as <strong>systemic lupus erythematosus</strong> (SLE),<strong> HIV</strong>, and <strong>Hepatitis C</strong>.</p>\n<p>Patients usually present with <strong>mucocutaneous bleeding</strong>, including <strong>petechiae</strong>, and <strong>purpura</strong>, often following minor trauma. Severe bleeding, such as gastrointestinal or intracranial hemorrhage, is rare.</p>\n<p>The <strong>diagnosis</strong> of ITP is primarily <strong>clinica</strong>l, supported by laboratory findings of<strong> isolated thrombocytopenia</strong> with a <strong>normal coagulation</strong> profile and <strong>peripheral smear</strong>. </p>\n<p>Initial Treatment is with glucocorticoids to reduce immune-mediated platelet destruction. For <strong>severe</strong> thrombocytopenia or bleeding, <strong>intravenous immunoglobulin </strong>(IVIg) and<strong> anti-D immunoglobulin</strong> can be used. For patients who relapse or do not respond to glucocorticoids, <strong>splenectomy</strong> is considered. <strong>Thrombopoietin receptor agonists </strong>like<strong> Eltrombpag</strong> and immunosuppressive agents like <strong>rituximab</strong> are other options.</p>\n<p>Other options</p>\n<p>Option A: <strong>ADAMTS 13 </strong>testing is indicated in patients with <strong>suspected thrombotic thrombocytopenic purpura (TTP)</strong>, which typically presents with <strong>microangiopathic hemolytic anemia </strong>characterized by <strong>low hemoglobin</strong> and <strong>schistocytes</strong> on a peripheral smear.</p>\n<p>Option C: <strong>Bone marrow biopsy</strong> is not routinely required for diagnosing ITP unless there are <strong>atypical findings </strong>on peripheral smear or a lack of response to treatment. It is generally reserved for cases where <strong>myelodysplastic syndrome</strong> or <strong>leukemia </strong>is suspected.</p>\n<p>Option D:  Antibodies against <strong>platelet factor 4 </strong>(PF-4) are seen in <strong>Heparin-induced thrombocytopenia </strong>(HIT) which may occur 5-10 days after initiation of Heparin. This patient is not taking Heparin.</p><hr><h3>Related Pearl: Idiopathic/Immune thrombocytopenic purpura (ITP)</h3><p>It is characterized by</p>\n<ul>\n<li>Isolated thrombocytopenia&mdash;the<strong>&nbsp;</strong>presence of antibody against platelet membrane glycoprotein and subsequent destruction in reticuloendothelial system</li>\n<li>Normal bone marrow&mdash;normal or even increased number of megakaryocytes</li>\n<li>Absence of other causes of thrombocytopenia.<strong>&nbsp;</strong></li>\n</ul>\n<p><strong>Types:</strong></p>\n<p>Acute (&lt;6 months) and chronic (&gt;6 months)<strong>&nbsp;</strong>idiopathic/immune thrombocytopenic purpura (ITP)</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p><strong>Acute ITP</strong></p>\n</td>\n<td>\n<p><strong>Chronic ITP</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Peak incidence</p>\n</td>\n<td>\n<p>2<strong>&ndash;</strong>6 years</p>\n</td>\n<td>\n<p>20<strong>&ndash;</strong>40 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sex predilection</p>\n</td>\n<td>\n<p><strong>None</strong></p>\n</td>\n<td>\n<p><strong>female: male ratio of 3:1&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antecedent infection</p>\n</td>\n<td>\n<p><strong>Common 1 to&nbsp;</strong><strong>3 weeks before</strong></p>\n</td>\n<td>\n<p><strong>Unusual</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Onset of bleeding</p>\n</td>\n<td>\n<p>Abrupt</p>\n</td>\n<td>\n<p>Insidious</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Platelet count</p>\n</td>\n<td>\n<p>&lt;20000/microlitre</p>\n</td>\n<td>\n<p>30<strong>&ndash;</strong>80000/microlitre</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Eosinophilia/lymphocytosis</p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Duration</p>\n</td>\n<td>\n<p>2<strong>&ndash;</strong>6 weeks</p>\n</td>\n<td>\n<p>Months or years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Spontaneous remission</strong></p>\n</td>\n<td>\n<p><strong>80% of cases</strong></p>\n</td>\n<td>\n<p><strong>Uncommon</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6464",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following are included in the International Society on Thrombosis and Haemostasis (ISTH) diagnostic criteria for DIC?<div class='question-desc-html'><ol>\n<li>PT</li>\n<li>D-Dimer </li>\n<li>Platelet count</li>\n<li>APTT</li>\n<li>Fibrinogen</li>\n<li>Thrombin time</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2, 4, 5, 6"
        },
        {
          "id": 2,
          "text": "1, 2, 4, 5, 6"
        },
        {
          "id": 3,
          "text": "1, 2, 3, 5"
        },
        {
          "id": 4,
          "text": "1, 2, 3, 4, 6"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The ISTH criteria include <strong>platelet count, D-dimer, fibrinogen, </strong>and <strong>prothrombin time,</strong> therefore option C is correct.</p>\n<p>The <strong>ISTH</strong> has created a scoring system to help diagnose overt DIC. This system evaluates <strong>platelet count</strong>,<strong> D-dimer</strong> levels, <strong>prothrombin time</strong> (PT), and <strong>fibrinogen levels</strong>, assigning points based on the severity of each parameter. The total score derived from these points assists in the diagnosis of DIC:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>PARAMETER</strong></td>\n<td><strong>VALUE</strong></td>\n<td><strong>POINTS</strong></td>\n</tr>\n<tr>\n<td><strong><span>Platelets</span></strong></td>\n<td><span>&gt;100,000</span><br /><span>&gt;50,000 but &lt;100,000</span><br /><span>&lt;50,000</span></td>\n<td><span>0</span><br /><span>1</span><br /><span>2</span></td>\n</tr>\n<tr>\n<td><strong><span>D-dimer</span></strong></td>\n<td><span>Normal </span><br /><span>Moderate increase</span><br /><span>Severe increase</span></td>\n<td><span>0</span><br /><span>2</span><br /><span>3</span></td>\n</tr>\n<tr>\n<td><strong><span>Prothrombin time (PT) prolongation</span></strong></td>\n<td><span>&lt;3 s</span><br /><span>3-&lt;6 s</span><br /><span>&gt;6s</span></td>\n<td><span>0</span><br /><span>1</span><br /><span>2</span></td>\n</tr>\n<tr>\n<td><strong><span>Fibrinogen</span></strong></td>\n<td><span>&gt;1 g/L</span><br /><span>&lt;1 g/L</span></td>\n<td><span>0</span><br /><span>1</span></td>\n</tr>\n<tr>\n<td><strong><span>Total score</span></strong></td>\n<td> </td>\n<td><strong><span>&lt;5 Low-grade DIC</span></strong><br /><strong><span>&gt;5 Overt DIC</span></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Disseminated intravascular coagulation </strong>(DIC) is an acquired syndrome characterized by the widespread activation of <strong>blood clotting factors</strong> within blood vessels,  throughout the body. This can result in <strong>multiple organ dysfunction</strong> and severe bleeding due to the consumption of platelets and coagulation factors. The primary mechanism of DIC involves the uncontrolled generation of thrombin through pathways leading to sustained <strong>coagulation activation</strong>, the <strong>formation of fibrin</strong>, and the <strong>consumption of clotting factors</strong> and <strong>platelets</strong>.</p>\n<p><strong>Infections </strong>are the most frequent cause of DIC.</p>\n<p>The following<strong> lab findings</strong> are seen in DIC: </p>\n<ol>\n<li>Decreased platelet count</li>\n<li>Prolonged PT/TT</li>\n<li>Prolonged activated partial thromboplastin time (aPTT)</li>\n<li>Decreased fibrinogen</li>\n<li>Elevated fibrin degradation products (D-dimers)</li>\n<li>Peripheral smear: microangiopathic hemolytic anemia in DIC with schistocytes (fragmented red blood cells)</li>\n</ol>\n<p>The <strong>treatment</strong> involves<strong> platelet transfusion</strong> when platelet counts are below 10,000-20,000/μL. Replacement of <strong>fibrinogen</strong> and <strong>coagulation factors</strong> is with <strong>fresh frozen plasma</strong> (FFP) along with <strong>cryoprecipitate </strong>or <strong>fibrinogen concentrate</strong>.</p>\n<p>In cases of <strong>low-grade DIC</strong> associated with<strong> solid tumors</strong> or <strong>acute promyelocytic leukemia</strong> low doses of continuous-infusion<strong> heparin</strong> have been effective.</p><hr><h3>Related Pearl: Parameters of the coagulation pathway and its uses</h3><p><strong> Parameters of the coagulation pathway and its uses</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Parameter </strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>Prothrombin Time (PT)</td>\n<td>It is used to monitor the functioning of the extrinsic and the common coagulation pathways. Normal PT is 11–13 seconds.</td>\n</tr>\n<tr>\n<td>Activated partial thromboplastin time (aPTT)</td>\n<td>It is used to monitor the functioning of the intrinsic and the common coagulation pathways. Normal aPTT is 25–35 seconds. A relatively rare cause of prolonged aPTT is the presence of antibodies against coagulation plasma proteins called inhibitors. It can be seen due to the following reasons: Hemophilia A and B patients receiving clotting factors to control their bleeding episodes, Pregnancy, Autoimmune diseases, Malignancies (lymphoma, prostate cancer), and Dermatologic conditions.</td>\n</tr>\n<tr>\n<td>Thrombin time (TT)</td>\n<td>It is used for testing the conversion of fibrinogen into fibrin and depends on adequate fibrinogen levels. </td>\n</tr>\n<tr>\n<td>Bleeding time (BT)</td>\n<td>It is the time taken for a standardized skin puncture to stop bleeding. It tests the ability of blood vessels to constrict and platelets to form a hemostatic plug. </td>\n</tr>\n<tr>\n<td>Fibrin degradation products (FDPs)</td>\n<td>They are used to assess the fibrinolytic activity, and they are increased in disseminated intravascular coagulation (DIC). </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Causes of Disseminated Intravascular Coagulation (DIC)</h3><p>Disseminated intravascular coagulation (DIC) is an acute, subacute, or chronic thrombohemorrhagic disorder occurring as a secondary complication in a variety of diseases. It is characterized by the activation of the coagulation sequence that leads to the formation of microthrombi throughout the microcirculation of the body. As a consequence of the thrombotic diathesis, there is a consumption of platelets, fibrin, and coagulation factors and, secondarily, activation of fibrinolytic mechanisms.</p>\n<p><strong>Causes of DIC:</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Obstetric complications</strong></td>\n<td>\n<ul>\n<li>Abruptio placenta</li>\n<li>Retained dead fetus</li>\n<li>Septic abortion</li>\n<li>Amniotic fluid embolism</li>\n<li>Toxemia</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Infections</strong></td>\n<td>\n<ul>\n<li>Sepsis</li>\n<li>Meningococcemia</li>\n<li>Histoplasmosis</li>\n<li>Aspergillosis</li>\n<li>Malaria</li>\n<li>Toxemia&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Neoplasms</strong></td>\n<td>\n<ul>\n<li>Ca. pancreas</li>\n<li>Ca. prostate</li>\n<li>Ca. lung</li>\n<li>Acute promyelocytic leukemia</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Massive Tissue Injury</strong></td>\n<td>\n<ul>\n<li>Traumatic injury</li>\n<li>Burns</li>\n<li>Extensive surgery</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Miscellaneous</strong></td>\n<td>\n<ul>\n<li>Acute intravascular hemolysis</li>\n<li>Snake bite</li>\n<li>Shock</li>\n<li>Stroke</li>\n<li>Vasculitis</li>\n<li>Aortic aneurysm</li>\n<li>Liver disease</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6459",
      "difficulty": "hard"
    },
    {
      "text": "Two patients, A and B, present with frequent nosebleeds. On further investigations, it is revealed that they have a deficiency of glycoprotein Ib/IX and glycoprotein IIb–IIIa respectively. Which of the following lab tests will you order to confirm their diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Ristocetin cofactor assay"
        },
        {
          "id": 2,
          "text": "Platelet count"
        },
        {
          "id": 3,
          "text": "Bleeding time"
        },
        {
          "id": 4,
          "text": "PT/PTT"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ristocetin cofactor assay</strong> can be used to differentiate patient A who has <strong>Bernard–Soulier syndrome(deficiency of Gp Ib-IX receptor) </strong>from patient B who has<strong> Glanzmann's thrombasthenia(deficiency Gp IIb/IIIa receptor)</strong><strong>.</strong></p>\n<p>This is because the ristocetin cofactor assay tests the integrity of the <strong>Gp Ib binding</strong> to the <strong>Von Willebrand factor</strong>. This will be normal in patients with Glanzmann's. So, this test can be used to differentiate <strong>Bernard–Soulier syndrome </strong>(<strong>abnormal</strong> ristocetin aggregation) from <strong>Glanzmann's thrombasthenia</strong> (<strong>normal</strong> ristocetin aggregation) .</p>\n<p><strong>B</strong><strong>ernard–Soulier syndrome</strong> and <strong>Glanzmann’s thrombasthenia </strong>are caused due to <strong>deficiency of Gp Ib-IX receptor </strong>and<strong> deficiency Gp IIb/IIIa receptor</strong> respectively. In both these conditions, <strong>platelet count</strong> and <strong>PT/PTT</strong> is <strong>normal,</strong> with only an <strong>increase in bleeding time. </strong></p>\n<p>Specific <strong>platelet aggregation tests</strong> with collagen, ADP, etc. <strong>will fail</strong> to bring about platelet aggregation in <strong>Glanzmann’s thrombasthenia. </strong>Whereas, in <strong>B</strong><strong>ernard–Soulier syndrome,</strong> platelet aggregation tests are<strong> normal.</strong></p>\n<p>Other options:</p>\n<p>Option B: Platelet count is not specific enough to diagnose deficiencies of the mentioned glycoproteins.</p>\n<p>Options C: Bleeding time assesses overall platelet function but does not directly diagnose the specific glycoprotein deficiencies.</p>\n<p>Options D: PT/PTT are coagulation tests and can help identify clotting disorders but are not specific for glycoprotein deficiencies.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/782ae3af1df243909f30610685a47c0ex1279x1689.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Platelet disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a852ed6ad094d22b4add695e1529e87x1280x1740.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Finding</strong></p>\n</td>\n<td>\n<p><strong>Bernard&ndash;Soulier syndrome</strong></p>\n</td>\n<td>\n<p><strong>Glanzmann&rsquo;s thrombasthenia</strong></p>\n</td>\n<td>\n<p><strong>von Willebrand Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Inheritance</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>Most common (type 1): Autosomal dominant</td>\n</tr>\n<tr>\n<td>&nbsp;Defect</td>\n<td>\n<p>Absence of Gp Ib-IX-V receptor</p>\n</td>\n<td>Absence of&nbsp;Gp IIb/IIIa receptor</td>\n<td>\n<p>Type 1: Partial quantitative deficiency of&nbsp;von Willebrand factor (VWF)</p>\n<p>Type 2: Qualitative defect of VWF</p>\n<p>Type 3: Complete quantitative deficiency of VWF&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Mechanism</td>\n<td>\n<p>Lack of Gp Ib-IX-V prevents platelet <strong>adhesion</strong> to VWF</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Platelets cannot <strong>aggregate</strong> as Gp IIb/IIIa normally binds&nbsp;fibrinogen and forms bridges between platelets&nbsp;</p>\n</td>\n<td>\n<p>There are 2 mechanisms:</p>\n<p>Platelet <strong>adhesion</strong> defect - due to absent vWF that normally binds to GPIB-IX and collagen in the subendothelium</p>\n<p>Factor VIII deficiency as&nbsp;vWF usually prevents its degradation</p>\n</td>\n</tr>\n<tr>\n<td>Platelet count&nbsp;</td>\n<td>Normal platelet count/ mild thrombocytopenia&nbsp;</td>\n<td>Normal</td>\n<td>Normal (except in type 2B- thrombocytopenia)</td>\n</tr>\n<tr>\n<td>Platelet morphology</td>\n<td>Large platelets/ megathrombocytes with dense granules</td>\n<td>Normal</td>\n<td>&nbsp;Normal/ large</td>\n</tr>\n<tr>\n<td>Bleeding time</td>\n<td>\n<p>Prolonged</p>\n</td>\n<td>Prolonged</td>\n<td>&nbsp;Prolonged</td>\n</tr>\n<tr>\n<td>Platelet aggregation tests (collagen, ADP, thrombin)</td>\n<td>Normal</td>\n<td>Abnormal</td>\n<td>&nbsp;Normal</td>\n</tr>\n<tr>\n<td>Ristocetin aggregation test</td>\n<td>\n<p>Abnormal (platelets does not aggregate)</p>\n<p>Does not normalize&nbsp;after addition of normal serum</p>\n</td>\n<td>\n<p>Normal</p>\n<p>(aggregation of platelets)</p>\n</td>\n<td>Abnormal, Normalizes after addition of normal serum</td>\n</tr>\n<tr>\n<td>VWF factor levels</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;Decreased</td>\n</tr>\n<tr>\n<td>PT/PTT</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;PT normal, aPTT prolonged</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Summary of Laboratory findings in Hemostatic Disorders</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Platelet count</strong></p>\n</td>\n<td>\n<p><strong>Bleeding time</strong></p>\n</td>\n<td>\n<p><strong>PT</strong></p>\n</td>\n<td>\n<p><strong>APTT</strong></p>\n</td>\n<td>\n<p><strong>Comments</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>ITP</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Nomal</p>\n</td>\n<td>\n<p>Auto-Antibodies against IIb-IIIa or Ib-IX</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glanzmann thrombasthenia</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in IIb/IIIa</p>\n<p>Autosomal recessive</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Bernard&ndash; Soulier syndrome</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in Ib/IX</p>\n<p>Autosomal recessive</p>\n<p>Large platelets</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>von Willebrand disease</p>\n</td>\n<td>\n<p>Low or normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>3 subtypes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hemophilia A and B</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>X-linked inheritance</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Liver disease</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Vitamin K deficiency</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>DIC</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increase in fibrin degradation products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Aspirin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Warfarin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ITP:&nbsp;Immune thrombocytopenic purpura</p>\n<p>DIC: Disseminated intravasculation coagulation</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9364",
      "difficulty": "medium"
    },
    {
      "text": "A grandmother has noticed that her granddaughter's umbilical stump hasn't fallen off even after 4 weeks. On examination, the pediatrician notices mild bruising. Which of the following clotting factor deficiencies should he suspect?",
      "choices": [
        {
          "id": 1,
          "text": "Factor VII deficiency"
        },
        {
          "id": 2,
          "text": "Factor IX deficiency"
        },
        {
          "id": 3,
          "text": "Factor XI deficiency"
        },
        {
          "id": 4,
          "text": "Factor XIII deficiency"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Delayed separation</strong> of the umbilical stump&nbsp;beyond 4 weeks is a characteristic finding seen in&nbsp;<strong>factor XIII deficiency.</strong> However, these findings can also be seen in septicemia or local infections.</p>\n<p><strong>Factor XIII</strong> is responsible for the <strong>crosslinking of fibrin to stabilize</strong> the fibrin clot, symptoms&nbsp;of delayed hemorrhage are secondary to the instability of the clot. Typically, patients have trauma one day and then have a bruise or hematoma the next day.</p>\n<p>Results of the<strong>&nbsp;usual screening tests for hemostasis</strong> are <strong>normal</strong> in patients with factor XIII deficiency. Screening tests for factor XIII deficiency are based on the observation that there is increased solubility of the clot because of the failure of cross-linking.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3115",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is true regarding the classical hemorrhagic disease of the newborn?",
      "choices": [
        {
          "id": 1,
          "text": "Age of onset is 1-6 months"
        },
        {
          "id": 2,
          "text": "Age of onset is 2-7 days"
        },
        {
          "id": 3,
          "text": "Age of onset is 0-24 hours"
        },
        {
          "id": 4,
          "text": "Age of onset is >6 months"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The age of onset of classical hemorrhagic disease of the newborn is<strong> 2-7 days</strong>.&nbsp;</p>\n<p><strong>Hemorrhagic disease of the newborn</strong> is caused by a&nbsp;transient deficiency of <strong>vitamin K</strong>&ndash;dependent factors,<strong>&nbsp;factors II, VII, IX, and X.</strong></p>\n<p>Causes include:</p>\n<ul>\n<li>Lack of free vitamin K from the mother</li>\n<li>Absence of the bacterial intestinal flora normally responsible for the synthesis of vitamin K.</li>\n</ul>\n<div class=\"page\" title=\"Page 1531\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Classical</strong> hemorrhagic disease of the newborn&nbsp;occurs early in the newborn period, typically <strong>between day 2 and 7 of life</strong>, and most often in exclusively breastfeeding infants who did not receive vitamin K prophylaxis at birth.</p>\n<div class=\"page\" title=\"Page 1531\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Early-onset</strong> vitamin K deficiency bleeding (<strong>after birth but in first 24 hr</strong>) occurs if the mother has been treated chronically with certain drugs that interfere with vitamin K absorption or function. (Option C)</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 1531\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Late-onset</strong> vitamin K deficiency bleeding (<strong>1-6 months of life</strong>) is usually associated with conditions that feature malabsorption of the fat-soluble vitamin K, such as cystic fibrosis, neonatal hepatitis, or biliary atresia.&nbsp;</p>\n</div>\n</div>\n</div>\n<p>Hemorrhagic disease of the newborn<strong>&nbsp;</strong>is responsive to and prevented by <strong>vitamin K therapy</strong> (0.5-1 mg of phytonadione).</p><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9457",
      "difficulty": "medium"
    },
    {
      "text": "A child is brought with hemarthrosis following a trivial trauma. On testing, you find an isolated prolongation of prothrombin time. Which of the following clotting factors is likely to be deficient in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Factor VII"
        },
        {
          "id": 2,
          "text": "Factor VIII"
        },
        {
          "id": 3,
          "text": "Factor IX"
        },
        {
          "id": 4,
          "text": "Factor II"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Hemarthrosis</strong>&nbsp;following a trivial trauma is suggestive of a bleeding disorder and that associated with an <strong>isolated prolonged</strong> <strong>prothrombin</strong> <strong>time</strong>&nbsp;shows that<strong>&nbsp;clotting factor VII </strong>is likely to be <strong>deficient</strong> in this patient.&nbsp;&nbsp;</p>\n<p><strong>Prothrombin time </strong>(PT) assesses the <strong>extrinsic pathway</strong> and common coagulation pathways. It measures the time (in seconds) needed for plasma to clot after the addition of an exogenous source of tissue thromboplastin and calcium ions. A prolonged PT can occur due to deficiencies/dysfunction of factors <strong>V</strong>, <strong>VII</strong>, <strong>X</strong>, <strong>II</strong> (prothrombin), and fibrinogen.</p>\n<p><strong>Activated partial thromboplastin time </strong>(aPTT) assesses the <strong>intrinsic pathway</strong> and common coagulation pathways. It measures the time needed for plasma to clot after the addition of kaolin (to activate XII), cephalin (substitutes platelet phospholipids), and calcium ions. aPTT is prolonged due to dysfunction of V, VIII, IX, X, XI, XII, prothrombin, and fibrinogen.&nbsp;&nbsp;</p>\n<p>Thus this shows that factor VII deficiency is associated with isolated prolongation of PT.</p>\n<p>Clotting factor VII deficiency, otherwise known as <strong>Alexander's disease</strong>, is usually inherited as an autosomal recessive disease. It can present with<strong> recurrent</strong> episodes of <strong>bleeding</strong> into joints, muscles, and closed spaces that start spontaneously or following an injury. Diagnosis can be made by lab results of PT and aPTT and confirmed with factor VII assay. Patients are treated with recombinant factor VIIa.&nbsp;&nbsp;</p>\n<p>Other options:</p>\n<p>Option B &amp; C: <strong>Factor VIII </strong>and&nbsp;<strong>IX&nbsp;deficiency</strong>, otherwise known as&nbsp;<strong>hemophilia A &amp; B </strong>respectively,&nbsp;are associated with <strong>isolated</strong>&nbsp;<strong>prolonged aPTT</strong>.</p>\n<p>Option D:<strong> Factor II deficiency</strong> is associated with<strong>&nbsp;prolongation </strong>of both <strong>PT</strong> and<strong> aPTT.</strong></p><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><hr><h3>Related Pearl: Summary of Laboratory findings in Hemostatic Disorders</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Platelet count</strong></p>\n</td>\n<td>\n<p><strong>Bleeding time</strong></p>\n</td>\n<td>\n<p><strong>PT</strong></p>\n</td>\n<td>\n<p><strong>APTT</strong></p>\n</td>\n<td>\n<p><strong>Comments</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>ITP</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Nomal</p>\n</td>\n<td>\n<p>Auto-Antibodies against IIb-IIIa or Ib-IX</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glanzmann thrombasthenia</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in IIb/IIIa</p>\n<p>Autosomal recessive</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Bernard&ndash; Soulier syndrome</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in Ib/IX</p>\n<p>Autosomal recessive</p>\n<p>Large platelets</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>von Willebrand disease</p>\n</td>\n<td>\n<p>Low or normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>3 subtypes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hemophilia A and B</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>X-linked inheritance</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Liver disease</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Vitamin K deficiency</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>DIC</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increase in fibrin degradation products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Aspirin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Warfarin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ITP:&nbsp;Immune thrombocytopenic purpura</p>\n<p>DIC: Disseminated intravasculation coagulation</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0253",
      "difficulty": "medium"
    },
    {
      "text": "A 25-year-old lady presents with generalised weakness and recurrent epistaxis. On examination, the spleen is not palpable. Blood investigations reveal Hb of 5 g/dL, platelet count of 15,000/μL, and WBC count of 3000/μL. What findings are expected to be seen in a bone marrow biopsy of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Macrophages with characteristic crumbled tissue paper appearance."
        },
        {
          "id": 2,
          "text": "Numerous needle-like azurophilic granules in the cytoplasm of the promyelocytes."
        },
        {
          "id": 3,
          "text": "Hypocellularity with fatty infiltration"
        },
        {
          "id": 4,
          "text": "Erythroid hyperplasia with pathognomonic ring sideroblasts"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given clinical scenario, the presence of <strong>generalised weakness, recurrent epistaxis, </strong><span><strong>impalpable spleen</strong>&nbsp;</span>and blood investigations showing <strong>pancytopenia,</strong> are suggestive of <strong>Aplastic anemia. </strong>Bone marrow biopsy reveals <strong>hypocellularity</strong> with&nbsp;<strong>fatty infiltration.</strong></p>\n<p><strong>Aplastic anemia</strong>&nbsp;is a syndrome of chronic primary&nbsp;<strong>hematopoietic failure</strong>. This results in&nbsp;<strong>pancytopenia</strong> (anemia, neutropenia, and thrombocytopenia).&nbsp;The patient will have</p>\n<ul>\n<li>Decreased red blood cells leading to&nbsp;<strong>anemia</strong></li>\n<li>Decreased white blood cells leading to recurrent&nbsp;<strong>infections</strong></li>\n<li>Decreased platelets leading to&nbsp;<strong>petechiae</strong>&nbsp;and ecchymoses.</li>\n</ul>\n<p>Many other leukemias and lymphomas may have a similar presentation. However,&nbsp;<strong>splenomegaly</strong>&nbsp;is&nbsp;<strong>characteristically absent</strong>&nbsp;in these patients.&nbsp;</p>\n<p>The bone marrow is markedly <strong>hypocellular.</strong> It is largely devoid of hematopoietic cells. Marrow aspirates yield a&nbsp;<strong>dry tap</strong>&nbsp;having&nbsp;<strong>only fat cells</strong>, fibrous stroma, lymphocytes, and plasma cells. Aplasia is best appreciated in&nbsp;<strong>marrow biopsies.&nbsp;</strong></p>\n<p>The images given below show the normal and hypocellular bone marrow.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f327985138be43de83d043bd95a6e896x1280x1502.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8cc18d7855e5451bbaab4ca25821d8ddx1280x1151.JPEG\" alt=\"Explanation Image\"><p>Treatment includes:</p>\n<ul>\n<li><strong>Hematopoietic stem cell transplantation</strong>&nbsp;- best method of management in <strong>young patients.</strong></li>\n<li><strong>Antithymocyte globulin</strong>&nbsp;with <strong>cyclosporine - </strong>elderly patients and patients without HLA-matched donors.</li>\n<li><strong>Eltrombopag</strong> - a thrombopoietin analog used as an add-on therapy.</li>\n</ul>\n<p>Other options:</p>\n<p>Option A:&nbsp;Bone marrow examination showing <strong>macrophages</strong> with&nbsp;characteristic<strong> crumbled tissue paper appearance </strong>is seen in<strong> Gaucher disease,</strong> due to <strong>glucocerebrosidase deficiency. </strong>The patients present with <strong>haematological</strong>&nbsp;<strong>abnormalities</strong>,&nbsp;<strong>organomegaly</strong>, and <strong>pathological fractures</strong>.&nbsp;</p>\n<p>Option B: <strong>Acute myeloid leukaemia</strong> is most commonly seen in&nbsp;<strong>elderly</strong>&nbsp;people. Histopathology from bone marrow aspirate reveals&nbsp;<strong>Auer rods</strong> (needle-like azurophilic granules) in the cytoplasm of the <strong>promyelocytes</strong> (black arrow) along with a large, uniform population of cells <strong>(myeloblasts)</strong> with prominent nucleoli (yellow arrow).</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2d5a413779f1468dac68342811b4bb48x352x512.JPEG\" alt=\"Explanation Image\"><p>Option D: Bone marrow examination showing <strong>e</strong><strong>rythroid hyperplasia</strong>&nbsp;with pathognomonic&nbsp;<strong>ring sideroblasts</strong> is seen in <strong>s</strong><strong><strong>ideroblastic anemia.</strong></strong> Sideroblastic anemia are a group of disorders characterized by the presence of&nbsp;<strong>nucleated</strong> red cells&nbsp;(normoblasts) containing <strong>non-heme</strong> siderotic granules and stain&nbsp;<strong>prussian</strong>&nbsp;<strong>blue</strong> positive (sideroblasts).<strong> </strong>They can be also seen in <strong>myelodysplastic syndrome</strong> and <strong>lead poisoning.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ff00d7fd5ef142f4b7787d10ce2aaf17x501x353.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG0218",
      "difficulty": "medium"
    },
    {
      "text": "A 58-year-old male patient comes to the medical outpatient department with increased frequency and burning micturition. He has a mechanical heart valve and is undergoing warfarin therapy for his transient ischaemic attacks. Urine is sent for culture and sensitivity and he is started on antibiotics. The next day he comes with complaints of excessive bleeding after a trivial injury. Which of the following antibiotics was most probably prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Tetracycline"
        },
        {
          "id": 2,
          "text": "Cotrimoxazole"
        },
        {
          "id": 3,
          "text": "Clindamycin"
        },
        {
          "id": 4,
          "text": "Cephalexin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The clinical vignette showing a man with a mechanical valve who is undergoing </span><strong><span data-preserver-spaces=\"true\">warfarin therapy</span></strong><span data-preserver-spaces=\"true\"> presenting with </span><strong><span data-preserver-spaces=\"true\">excessive bleeding</span></strong><span data-preserver-spaces=\"true\"> is most likely due to the administration of the antibiotic </span><strong><span data-preserver-spaces=\"true\">cotrimoxazole.</span></strong></p>\n<p><strong><span data-preserver-spaces=\"true\">Warfarin</span></strong><span data-preserver-spaces=\"true\"> is mainly </span><strong><span data-preserver-spaces=\"true\">metabolized </span></strong><span data-preserver-spaces=\"true\">by the</span><strong><span data-preserver-spaces=\"true\"> CYP2C9</span></strong><span data-preserver-spaces=\"true\"> enzyme. Drugs that inhibit the CYP2C9 enzyme, like cotrimoxazole, reduce the metabolism of warfarin and thus, enhance the anticoagulant effect of warfarin and increase the risk of bleeding.</span></p>\n<p><strong><span data-preserver-spaces=\"true\">Warfarin interactions</span></strong><span data-preserver-spaces=\"true\">:</span></p>\n<p><span data-preserver-spaces=\"true\">Interactions with warfarin can be caused due to alteration in the absorption and metabolism of the drug, the circulating levels of clotting factors, and the state of epithelial surface.</span></p>\n<p><span data-preserver-spaces=\"true\">Reduced efficacy:</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">Decreased absorption - COnjugation with cholestyramine</span></li>\n<li><span data-preserver-spaces=\"true\">Increased clearance - CYP2C9 activation by drugs (barbiturates, carbamazepine, rifampin)</span></li>\n<li><span data-preserver-spaces=\"true\">Reduced circulating volume - Nephrotic syndrome</span></li>\n<li><span data-preserver-spaces=\"true\">Resistance - High Vitamin K consumption, High circulating clotting factor levels in pregnancy</span></li>\n</ul>\n<p><span data-preserver-spaces=\"true\">Increased efficacy:</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">Drugs causing CYP2C9 inhibition:</span></li>\n<ul>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Amiodarone</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Azole antifungals</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Cimetidine</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Clopidogrel</span></li>\n<li class=\"ql-indent-1\"><strong><span data-preserver-spaces=\"true\">Cotrimoxazole</span></strong></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Disulfiram</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Isoniazid</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Metronidazole</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Fluoxetine</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Sulfinpyrazone</span></li>\n<li class=\"ql-indent-1\"><span data-preserver-spaces=\"true\">Zafirlukast</span></li>\n</ul>\n</ul>\n<p><span data-preserver-spaces=\"true\">Other options:</span></p>\n<p><span data-preserver-spaces=\"true\">Options A and D - <strong>Tetracycline</strong> and <strong>Cephalexin</strong> (belonging to cephalosporins) are almost completely metabolized and excreted by the kidneys and hence do not interact with Warfarin.</span></p>\n<p><span data-preserver-spaces=\"true\">Option C - <strong>Clindamycin</strong> is metabolized to N-demethylclindamycin and clindamycin sulfoxide, which are then excreted in the urine and bile. It does not cause CYP2C9 inhibition.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1184",
      "difficulty": "medium"
    }
  ]
}